

Edgar Filing: ACCEL8 TECHNOLOGY CORP - Form 8-K

ACCEL8 TECHNOLOGY CORP

Form 8-K

October 18, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 5, 2005

-----  
Date of Report (Date of earliest event reported):

ACCEL8 TECHNOLOGY CORPORATION  
-----

(Exact name of registrant as specified in charter)

Colorado -----	0-11485 -----	84-1072256 -----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

7000 North Broadway, Building 3-307, Denver, CO 80221  
-----

(Address of principal executive offices)

(303) 863-8808  
-----

Registrant's telephone number, including area code:

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

Effective October 5, 2005, Accelr8 Technology Corporation (the "Accelr8") and Promega Corporation ("Promega") entered into a Feasibility Testing Agreement

Edgar Filing: ACCEL8 TECHNOLOGY CORP - Form 8-K

(the "Feasibility Testing Agreement"). The following summary of the Feasibility Testing Agreement is qualified in its entirety by reference to the entire Feasibility Testing Agreement.

Pursuant to the Feasibility Testing Agreement, Accelr8 will focus on the development of a customized coating for glass slides for use by Promega and a potential short term supply of such glass slides, should the development be successful and Promega chooses Accelr8 to manufacture and supply slides for sale to third parties. The Feasibility Testing Agreement requires that the feasibility testing be divided into two phases. Promega will pay Accelr8 \$49,000 in return for Accelr8's performance under the Feasibility Testing Agreement. If Promega determined that Phase 1 is not successfully completed, Accelr8 will return \$22,000 to Promega and Accelr8 will have no further obligation under the Feasibility Testing Agreement. If both phases have been successfully completed, the materials developed meet Promega's product performance parameters, and Promega wishes to sell slides with the Customized Coating (as defined in the Feasibility Testing Agreement), the Accelr8 and Promega will enter into a license agreement.

Any invention developed under the Feasibility Testing Agreement that constitutes an improvement of Accelr8's Background Technology (as defined in the Feasibility Testing Agreement) shall be owned by Accelr8. Any other inventions shall be a joint invention owned by both Accelr8 and Promega. The Feasibility Testing Agreement, unless previously terminated, expires on September 30, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 17, 2005

ACCEL8 TECHNOLOGY CORPORATION

By: /s/ Thomas V. Geimer

-----  
Thomas V. Geimer, Chief Executive Officer